Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

By sjmartinez • November 9, 2023

Karpouzas GA, Szekanecz Z, Baecklund E, Mikuls TR, Bhatt DL, Wang C, Sawyerr GA, Chen Y, Menon S, Connell CA, Ytterberg SR, Mortezavi M. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. Ther Adv Musculoskelet Dis. 2023 Nov 6;15:1759720X231201047. doi: 10.1177/1759720X231201047. PMID: 37942277; PMCID: PMC10629315.

Tags: autoinflammatory conditions, DMARDs, Inflammation, outcome measures, Publications, Rheumatoid arthritis, Rheumatology

CAR immunotherapy in autoimmune diseases: promises and challenges

Yu J, Yang Y, Gu Z, Shi M, La Cava A, Liu A. CAR immunotherapy in autoimmune diseases: promises and challenges. Front Immunol. 2024 Oct[...]

Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure

Baghdadi JD, Wessel M, Dubberke ER, Lydecker A, Claeys KC, Alonso C, Coffey KC, Durkin M, Gonzales-Luna AJ, Guh AY, Kwon JH, Martin E, Mehrotra[...]

Tertiary Care Center Trends in Colonic Stent Placement over the Past Decade

Juakiem WY, Singh K, Ofosu A, Ramai D, Persaud A, Tabibian JH, Rodrigues-Pinto E, Girotra M, Barakat MT. Tertiary Care Center Trends in Colonic Stent[...]